AnchorDx, a China-based developer of cancer early detection solutions, announced on Wednesday that it has enrolled its first patient in the UriFind bladder cancer assay clinical trial in the United States.
The more than 1,000-patient multi-centre, prospective registration study is intended to assess the performance of the non-invasive, quantitative real-time PCR (qPCR) assay aimed at detecting two DNA methylation biomarkers in urine specimens from subjects suspected of having bladder cancer.
The United States Food and Drug Administration (FDA) granted a Breakthrough Device Designation (BTD) for the assay in July 2021. Outcomes of this clinical trial are intended to meet the needs for an application for a Premarketing Approval (PMA) to the FDA in the United States. The trial is likely to include around 10 sites of Urology clinics and three CAP/CLIA laboratories.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories